ASCO GU 2025 Press Releases

Viewing 1-11 of 11 articles

Bladder Cancer: Upstaging and Risk Mitigation with Blue Light Cystoscopy in NMIBC Featured at ASCO GU 2025

First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Mobile Prostate Cancer Screening Clinic Can Help Address Barriers to Serving High-Risk Communities

Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium

Early Survival Benefits Sustained over More than Five Years with Cabometyx® plus Nivolumab Versus Sunitinib in Advanced Renal Cell Carcinoma

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting

Clarity to Present COBRA and CLARIFY Abstracts at Two World-Leading Conferences